Browsing by Author "Ozaslan, Ersin"

Now showing items 1-2 of 2

Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less

Ozaslan, Ersin; Karaca, Halit; Koca, Sinan; Sevinc, Alper; Hacioglu, Bekir; Ozkan, Metin; Ozcelik, Melike; Duran, Ayse O.; Hacibekiroglu, Ilhan; Yildiz, Yasar; Tanriverdi, Ozgur; Menekse, Serkan; Aksoy, Asude; Bozkurt, Oktay; Urvay, Semiha; Uysal, Mukremin; Demir, Hacer; Ciltas, Aydin; Dane, Faysal (LIPPINCOTT WILLIAMS & WILKINS, 2017)

The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were ...
Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Ozaslan, Ersin; Topaloglu, Ulas Serkan; Inanc, Mevlude; Erdem, Umut Gokmen; Demir, Hacer; Arpaci, Erkan; Seker, Mehmet Metin; Karaaga, Mustafa; Kiziltepe, Melih; Eker, Baki; Ozkan, Metin (IMPRIMATUR PUBLICATIONS, 2017)

Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab ...